An interventional study of Ultrasound-Guided Subtransverse Interligamentary (STIL) Block and Ultrasound-Guided Thoracic Paravertebral Block (PVB) in Breast Cancer, sponsored by National Cancer Institute, Egypt. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Breast Neoplasms by National Cancer Institute, Egypt — 6 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · National Cancer Institute, Egypt.
Among the 20 studies in Breast Neoplasms by National Cancer Institute, Egypt, this one is the 14th largest by planned enrollment, is one of 3 that started in 2026, is one of 18 with no phase, and was the 20th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →6 of the 20 studies in Breast Neoplasms by National Cancer Institute, Egypt are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–60 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–60
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–70 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2
First in 2013; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 72 across 10,914 interventional studies indexed under Breast Neoplasms.
Median enrollment 85 across the 20 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute, Egypt is the lead sponsor of 134 studies on the registry; 30 are open to participants now.
3 of the studies in Breast Neoplasms by National Cancer Institute, Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07095569National Cancer Institute, EgyptShoulder Denervation for Post Mastectomy Irradiation Shoulder Pain | 2026-12-01 |
| NCT07650305National Cancer Institute, EgyptBilevel Erector Spinae Plane Block Versus Pectoserratus Block for Analgesia in Modified Radical Mastectomy | 2026-12-01 |
| NCT07950982National Cancer Institute, EgyptSTIL Block Versus Paravertebral Block for Pain Relief After Modified Radical Mastectomy | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Breast Neoplasms by National Cancer Institute, Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer surgery, particularly modified radical mastectomy (MRM), can cause significant postoperative pain. Effective pain management is important to improve patient comfort, facilitate recovery, reduce opioid consumption, and potentially decrease the risk of persistent post-mastectomy pain.
This randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided subtransverse interligamentary (STIL) block and thoracic paravertebral block (PVB) for postoperative pain relief in female patients undergoing modified radical mastectomy.
Eligible patients will be randomly allocated into three groups: the STIL block group, the PVB group, and a control group receiving general anesthesia without a regional block. Both regional blocks will be performed under ultrasound guidance at the T4 thoracic level using 25 mL of 0.25% bupivacaine combined with 4 mg dexamethasone.
Postoperative pain will be assessed using a visual analogue scale (VAS) at rest and during movement. The study will also evaluate postoperative morphine consumption, time to first rescue analgesia, intraoperative fentanyl requirements, recovery characteristics, patient satisfaction, postoperative nausea and vomiting, and block-related complications.
The primary objective is to compare postoperative pain scores at rest 24 hours after surgery between patients receiving STIL block and those receiving PVB.
The findings may help determine whether STIL block provides an effective alternative to thoracic paravertebral block for postoperative analgesia following modified radical mastectomy.
BACKGROUND AND RATIONALE:
Modified radical mastectomy (MRM) is a commonly performed surgical procedure for the management of breast cancer. Postoperative pain remains an important concern and may interfere with respiratory function, delay mobilization, prolong hospital stay, and negatively affect patient recovery and satisfaction.
Thoracic paravertebral block (PVB) is an established regional anesthesia technique for breast surgery that provides effective postoperative analgesia and reduces opioid requirements. However, it requires considerable technical expertise and carries potential complications, including pleural puncture, pneumothorax, vascular injury, and inadvertent neuraxial spread of local anesthetic.
The ultrasound-guided subtransverse interligamentary (STIL) block is a relatively novel paraspinal regional anesthesia technique. Local anesthetic is injected into the space between the transverse process and the intertransverse ligament, allowing spread toward the thoracic paravertebral space.
This study aims to compare the postoperative analgesic efficacy of STIL block with thoracic PVB in patients undergoing MRM.
STUDY DESIGN AND POPULATION:
This is a prospective, randomized, controlled clinical trial involving 60 female patients with breast cancer scheduled for modified radical mastectomy at the National Cancer Institute, Cairo University.
Eligible patients will be aged 18-65 years, have an ASA physical status of II-III, and a body mass index between 20 and 35 kg/m².
Patients will be randomly allocated into three equal groups, with 20 patients in each group:
Group I - STIL Block:
Patients will receive ultrasound-guided subtransverse interligamentary block at the T4 thoracic level before induction of general anesthesia.
Group II - Paravertebral Block:
Patients will receive ultrasound-guided thoracic paravertebral block at the T4 thoracic level before induction of general anesthesia.
Group III - Control:
Patients will receive general anesthesia without any regional nerve block.
INTERVENTION DETAILS:
Both regional anesthesia techniques will be performed approximately 30 minutes before induction of general anesthesia.
In the STIL group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the subtransverse interligamentary space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
In the PVB group, a 22-gauge echogenic spinal needle will be advanced under ultrasound guidance into the thoracic paravertebral space at T4. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
All patients will receive standardized general anesthesia and multimodal postoperative analgesia according to the study protocol.
GENERAL ANESTHESIA AND POSTOPERATIVE ANALGESIA:
General anesthesia will be induced using intravenous propofol, fentanyl, and rocuronium and maintained with sevoflurane in oxygen-enriched air.
All patients will receive intravenous paracetamol 1 g and ketorolac 30 mg as part of the multimodal analgesic regimen, subject to suitability.
Postoperative analgesia will include intravenous paracetamol 1 g and ketorolac 30 mg every 8 hours. Rescue analgesia will be provided using intravenous morphine 3 mg increments whenever the visual analogue scale (VAS) pain score is ≥4.
OUTCOME ASSESSMENT:
Primary Outcome:
The primary outcome is the postoperative pain score at rest, assessed using the visual analogue scale (VAS) 24 hours after surgery, comparing the STIL and PVB groups.
Secondary Outcomes:
BLINDING AND RANDOMIZATION:
Patients will be randomly allocated using a computer-generated randomization sequence and sequentially numbered opaque sealed envelopes.
The study will be double-blinded. Patients and postoperative outcome assessors will be unaware of group allocation. Regional blocks will be performed by an anesthesiologist who will not participate in postoperative data collection. Identical adhesive dressings will be applied to the thoracic area in all patients.
STATISTICAL ANALYSIS:
Data will be analyzed using IBM SPSS Statistics version 27. Appropriate parametric and nonparametric statistical tests will be used according to data distribution. A p-value ≤0.05 will be considered statistically significant.
**Inclusion Criteria:**
**Exclusion Criteria:**
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive ultrasound-guided Subtransverse Interligamentary (STIL) block at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
Procedure: Ultrasound-Guided Subtransverse Interligamentary (STIL) Block
Patients will receive ultrasound-guided thoracic Paravertebral Block (PVB) at the T4 thoracic level, performed approximately 30 minutes before induction of general anesthesia. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
Procedure: Ultrasound-Guided Thoracic Paravertebral Block (PVB)
Patients will receive general anesthesia without any regional anesthesia block. Intraoperative and postoperative analgesia will be provided according to the standardized multimodal analgesic protocol, including intravenous paracetamol and ketorolac, with intravenous morphine as rescue analgesia when the VAS pain score is ≥4.
Ultrasound-guided Subtransverse Interligamentary (STIL) block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane beneath the intertransverse ligament into the subtransverse interligamentary space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
Ultrasound-guided thoracic paravertebral block performed at the T4 thoracic level approximately 30 minutes before induction of general anesthesia. A 22-gauge echogenic spinal needle will be advanced in-plane toward the thoracic paravertebral space. Following negative aspiration, 25 mL of 0.25% bupivacaine combined with dexamethasone 4 mg will be injected incrementally.
Postoperative Pain Score at Rest at 24 Hours
Postoperative pain intensity at rest will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain), 24 hours after surgery. The primary comparison will be between the STIL block and paravertebral block groups.
Time frame: 24 hours after surgery
Postoperative Pain Scores at Rest and During Movement
Pain intensity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, both at rest and during movement.
Time frame: PACU, 1, 2, 4, 6, 12, and 18 hours after surgery
Plan to share: No — Individual participant data will not be shared with other researchers because no data-sharing plan has been established for this study. Study results will be disseminated through scientific publications, while participant confidentiality and data privacy will be maintained in accordance with institutional ethical requirements.
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Nov 2027, 11 months after the start.
Of 2,669 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 11 months is below that.
Counting every sponsor, half of 2,779 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute, Egypt →